UK small-cap RNS · 27 Oct 2026

Key = all announcements except routine filings (voting rights, buybacks, holdings, director forms), plus the ones that are part of a situation. Not investment advice.

1. 07:00
   Pennon Group PNN £1,747m

   Results Of Rights Issue Results

   Pennon Group plc (the “Company”) announces that the 7 for 15 Rights Issue of 220,257,997 New Ordinary Shares at 250 pence per New Ordinary Share announced on 7 October 2026 has closed for acceptances.

   Dilutive fundraise
   Follow
2. 07:00
   Revolution Beauty Group REVB £39m

   Half-year Results Results

   Revolution Beauty Group plc (AIM: REVB), the multi-channel mass beauty brand, today announces its unaudited Half Year Results for the six months ended 31 August 2026 (“H1 27” or the "Period").

   in linefirst since Oct 2023
   Follow
3. 07:00
   Ultimate Products ULTP £40m

   Audited Results for the Year Ended 31 July 2026 Results

   FY26 in line with expectations; continued focus on UP proprietary brands

   in line
   Follow
4. 07:00
   Shearwater Group SWG £17m

   FY26 Results Results

   Confirms the 27 July update: revenue £42.3m and adjusted EBITDA £2.6m (£2.5m flagged), a second year of growth, and statutory loss cut to £0.3m. Largely pre-announced, so little surprise.

   Not yet sorted £42.3m · 250% of mcapin lineoutlook positivefirst in 7 months

   Moved: £3.0m adjusted EBITDA in FY26 for full LTIP vesting: pending → missed – FY26 adjusted EBITDA came in at £2.6m, below the £3.0m needed for full LTIP vesting. · Brookcourt £25m telco contract: FY26 benefit shown in upgraded trading update → FY26 revenue recognised; results confirm · Software division return to growth: H1 revenue down 12%; renewals and new clients → FY26 revenue down 17%; growth targeted FY27
   Follow
5. 07:00
   Inspiration Healthcare Group IHC £17m

   Half-year Results Results

   FY27 revenue expectation is raised to at least £43m, backed by 26% underlying H1 growth, a growing pipeline and a planned consumables launch. This is another step up after earlier upgrades.

   Project milestones £43.0m · 259% of mcapahead of expectationsoutlook positive, raisedfirst in 8 months

   Moved: Sales momentum to continue into FY27; company expects to close FY27 slightly ahe: pending → on_track – Guidance is raised to at least £43m for FY27, with momentum expected to continue into FY28, consistent with finishing ahead of expectations. · Transfer infusion distribution to Micrel by January 2027 to focus on neonatal; n: pending → on_track – The Infusion Therapies transfer to Micrel remains set for 31 January 2027, and the staff moved on 1 July 2026. Net debt is £5.2m against £5.1m at the year end. · Grow consumables and service (recurring) revenue: pending → on_track – Underlying service revenue is up 21% and the first proprietary consumables launch is planned for Q4 FY27. Underlying consumables revenue was flat.
   Follow